Keros Therapeutics Updates Investor Presentation, Highlights Clinical Progress for Rinvatercept and Elritercept

summarizeSummary

Keros Therapeutics updated its corporate presentation, revealing plans to start a Phase 2 trial for Rinvatercept in DMD in Q2 2026 and engage regulators for an ALS Phase 2 trial in H2 2026, alongside progress on its Takeda-partnered Elritercept program.

check_boxKey Events

• Rinvatercept (KER-065) Phase 2 for DMD

  Keros plans to commence an open-label, multi-cohort Phase 2 basket clinical trial for Rinvatercept in patients with Duchenne Muscular Dystrophy (DMD) in the second quarter of 2026.

• Rinvatercept (KER-065) for ALS

  The company intends to engage regulators on the design of a Phase 2 clinical trial evaluating Rinvatercept in patients with Amyotrophic Lateral Sclerosis (ALS) in the second half of 2026.

• Elritercept (KER-050) Partnership Update

  The presentation highlights the ongoing global license agreement with Takeda Pharmaceuticals for Elritercept, including a $200 million upfront payment and over $1.1 billion in potential development, approval, and commercial milestone payments. The Phase 3 RENEW clinical trial for Elritercept in Myelodysplastic Syndromes is ongoing.

auto_awesomeAnalysis

This 8-K announces the update of Keros Therapeutics' corporate presentation for investor meetings. The presentation details significant clinical advancements for its pipeline. For Rinvatercept (KER-065), the company plans to initiate a Phase 2 trial for Duchenne Muscular Dystrophy (DMD) in Q2 2026 and engage regulators for a Phase 2 trial in Amyotrophic Lateral Sclerosis (ALS) in H2 2026. The presentation also provides an update on Elritercept (KER-050), reiterating the substantial Takeda partnership (upfront $200M, potential $1.1B milestones) and the ongoing Phase 3 RENEW trial for Myelodysplastic Syndromes (MDS). These updates provide concrete timelines for key programs and underscore the company's progress in advancing its therapeutic candidates.